

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number
WO 2004/113285 A1

(51) International Patent Classification⁷: C07C 323/56, A61K 31/192 [SE/SE]; AstraZeneca R & D Molndal, S-SE-431 83 Molndal (SE).

(21) International Application Number: PCT/GB2004/002599

(74) Agent: ASTRAZENECA; Global Intellectual Property, S-SE-151 85 Sodertalje (SE).

(22) International Filing Date: 16 June 2004 (16.06.2004)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only): ASTRAZENECA AB [SE/SE]; Sodertalje, S-SE-151 85 (SE).

(25) Filing Language: English

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:

(30) Priority Data:
0314260.1 19 June 2003 (19.06.2003) GB

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only): ASTRAZENECA AB [SE/SE]; Sodertalje, S-SE-151 85 (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ANDERSSON, Kjell [SE/SE]; AstraZeneca R & D Molndal, S-SE-431 83 Molndal (SE). LINDSTEDT-ALSTERMARK, Eva-Lotte [SE/SE]; AstraZeneca R & D Molndal, S-SE-431 83 Molndal (SE). SORENSEN, Henrik

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/113285 A1

(54) Title: PROCESS FOR THE PREPARATION OF RACEMIC 2-{[2-(4-HYDROXYPHENYL)ETHYL]THIO}-3-[4-(2-[(METHYLSULFONYL)OXY]PHENOXY)ETHYL]PHENYL]-PROPANOIC ACID

(57) Abstract: The present invention provides a process for the preparation of substantially racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-[(methylsulfonyl)oxy]phenoxy)ethyl]phenyl]-propanoic acid which comprises reacting 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-[(methylsulfonyl)oxy]phenoxy)ethyl]phenyl]-propanoic acid enriched in one enantiomer with a base in an inert solvent.

BEST AVAILABLE COPY